Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Test-retest Study of [18F]Florbetaben PET in Cardiac Amyloidosis
NCT06790394Phase 1Completed
- Sponsor
- Lantheus Holdings, Inc.
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of florbetaben in cardiac amyloidosis, sponsored by Lantheus Holdings, Inc. Primary endpoint: Test-Retest variability of cardiac [18F]florbetaben PET uptake at 73 days. Started Oct 2025; status: completed.
02
Drugs
florbetaben
03
Conditions
cardiac amyloidosis
Beyond the preview
Go deeper on NCT06790394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06790394.